Newgate Capital Management’s iShares Biotechnology ETF IBB Stock Holding History

Newgate Capital Management’s Portfolio IBB Stock Details IBB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q2	$425K	Buy	+4,959	New	+$445K	0.35%	60

Other funds holding IBB

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return

Citigroup New York $235B AUM 32.99% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

SG Americas Securities New York $92.9B AUM 36.98% 1-Year Est. Return

Societe Generale $14.1B AUM

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Newgate Capital Management's IBB Position: Q2 2016 in Review

Newgate Capital Management opened a new position in iShares Biotechnology ETF (IBB) in Q2 2016: 4,959 shares worth $425K. The stake represents 0.35% of the portfolio and ranks #60 among its holdings.

428 funds tracked by Wall St. Rank hold IBB as of Q2 2016.

Newgate Capital Management held 4,959 shares of iShares Biotechnology ETF worth $425K as of Q2 2016.
iShares Biotechnology ETF was a new Newgate Capital Management position in Q2 2016.
iShares Biotechnology ETF made up 0.35% of Newgate Capital Management's portfolio in Q2 2016, its #60 holding.
428 funds tracked by Wall St. Rank held iShares Biotechnology ETF as of Q2 2016.

Based on Newgate Capital Management's 13F filing for Q2 2016, filed 3 Aug 2016.